Recombinant human GH treatment increased levels of IGF-I Z-Score between baseline and 6 months ( from -0.7 + / -0.9 SD to 0.1 + / -1.1 SD , p = 0.01 ) and modestly decreased BF ( from 38.4 + / -7.8 % to 35.6 + / -7.5 % , p = 0.046 ) .
